Mesentech is a Vancouver biotechnology company developing therapies for musculoskeletal diseases and bone-related conditions. Public descriptions of the company emphasize prostaglandin prodrugs, bone-targeting delivery concepts, and clinical-stage programs such as irodanoprost for bone repair, along with preclinical oncology efforts targeting bone cancers and metastases. Its work is oriented toward selective tissue distribution and regenerative musculoskeletal therapeutics.